TXG Insider Trading

Insider Ownership Percentage: 10.03%
Insider Buying (Last 12 Months): $445,600.00
Insider Selling (Last 12 Months): $597,023.48

10x Genomics Insider Trading History Chart

This chart shows the insider buying and selling history at 10x Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

10x Genomics Share Price & Price History

Current Price: $13.01
Price Change: +0.30 (1.20%)
As of 07/3/2025 04:57 PM ET

This chart shows the closing price history over time for TXG up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AugSepOctNovDecJanFebMarAprMayJunJul$13.01Closing price on 07/06/25:

SEC Filings (Institutional Ownership Changes) for 10x Genomics (NASDAQ:TXG)

84.68% of 10x Genomics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TXG by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$404kbought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Read More on 10x Genomics

Today's Range

Now: $13.01
Low: $12.75
High: $13.14

50 Day Range

MA: $9.82
Low: $8.10
High: $13.01

52 Week Range

Now: $13.01
Low: $6.78
High: $24.76

Volume

2,002,826 shs

Average Volume

2,721,292 shs

Market Capitalization

$1.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Who are the company insiders with the largest holdings of 10x Genomics?

10x Genomics' top insider investors include:
  1. Serge Saxonov (CEO)
  2. Benjamin J Hindson (Insider)
  3. Adam Taich (CFO)
  4. Justin J Mcanear (CFO)
  5. James Wilbur (Insider)
  6. Alan Mateo (Director)
Learn More about top insider investors at 10x Genomics.

Who are the major institutional investors of 10x Genomics?

10x Genomics' top institutional shareholders include:
  1. Kera Capital Partners Inc. — 0.03%
Learn More about top institutional investors of 10x Genomics stock.

Which institutional investors are buying 10x Genomics stock?

Within the last quarter, TXG stock was purchased by institutional investors including:
  1. Kera Capital Partners Inc.